Ken Griffin Lexicon Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 42,700 shares of LXRX stock, worth $70,882. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,700

Previous 136,200 68.65%

Holding current value

$70,882

Previous $326,000 78.22%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.54 - $2.28 $3.5 Million - $5.19 Million	2,274,979 Added 1691.72%	2,409,456 $4.05 Million
Q1 2024 May 15, 2024	SELL	$1.3 - $3.58 $847,187 - $2.33 Million	-651,683 Reduced 82.89%	134,477 $322,000
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.53 $784,249 - $1.2 Million	784,249 Added 41038.67%	786,160 $1.2 Million
Q3 2023 Nov 14, 2023	SELL	$1.06 - $2.33 $435,032 - $956,250	-410,408 Reduced 99.54%	1,911 $2,000
Q2 2023 Aug 14, 2023	BUY	$2.15 - $3.49 $648,203 - $1.05 Million	301,490 Added 272.03%	412,319 $944,000
Q1 2023 May 15, 2023	SELL	$1.99 - $2.68 $102,180 - $137,609	-51,347 Reduced 31.66%	110,829 $269,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $2.56 $62,969 - $89,556	34,983 Added 27.5%	162,176 $309,000
Q3 2022 Nov 14, 2022	SELL	$1.94 - $3.43 $74,662 - $132,006	-38,486 Reduced 23.23%	127,193 $306,000
Q2 2022 Aug 15, 2022	SELL	$1.31 - $2.69 $374,834 - $769,697	-286,133 Reduced 63.33%	165,679 $308,000
Q1 2022 May 16, 2022	BUY	$1.95 - $3.89 $816,593 - $1.63 Million	418,766 Added 1267.22%	451,812 $945,000
Q4 2021 Feb 14, 2022	SELL	$3.81 - $6.16 $52,616 - $85,069	-13,810 Reduced 29.47%	33,046 $130,000
Q3 2021 Nov 15, 2021	BUY	$3.38 - $5.35 $119,053 - $188,443	35,223 Added 302.79%	46,856 $225,000
Q2 2021 Aug 16, 2021	SELL	$4.12 - $5.87 $497,939 - $709,442	-120,859 Reduced 91.22%	11,633 $53,000
Q1 2021 May 17, 2021	BUY	$3.45 - $9.09 $204,271 - $538,209	59,209 Added 80.8%	132,492 $778,000
Q1 2020 May 15, 2020	SELL	$1.8 - $4.28 $441,952 - $1.05 Million	-245,529 Reduced 77.01%	73,283 $143,000
Q4 2019 Feb 14, 2020	BUY	$3.16 - $5.15 $359,747 - $586,296	113,844 Added 55.54%	318,812 $1.32 Million
Q3 2019 Nov 14, 2019	SELL	$1.2 - $6.66 $405,334 - $2.25 Million	-337,779 Reduced 62.24%	204,968 $616,000
Q2 2019 Aug 14, 2019	BUY	$5.35 - $7.11 $1.24 Million - $1.64 Million	231,120 Added 74.17%	542,747 $3.41 Million
Q1 2019 May 15, 2019	SELL	$4.36 - $7.94 $105,490 - $192,108	-24,195 Reduced 7.2%	311,627 $0
Q4 2018 Feb 14, 2019	BUY	$6.15 - $10.51 $1.98 Million - $3.39 Million	322,110 Added 2349.11%	335,822 $2.23 Million
Q3 2018 Nov 13, 2018	SELL	$10.32 - $13.06 $931,968 - $1.18 Million	-90,307 Reduced 86.82%	13,712 $0
Q2 2018 Aug 10, 2018	SELL	$7.8 - $13.69 $110,775 - $194,425	-14,202 Reduced 12.01%	104,019 $0
Q1 2018 May 11, 2018	SELL	$7.86 - $11.39 $400,490 - $580,354	-50,953 Reduced 30.12%	118,221 $1.01 Million
Q4 2017 Feb 09, 2018	BUY	$8.77 - $12.28 $921,446 - $1.29 Million	105,068 Added 163.9%	169,174 $1.67 Million
Q3 2017 Nov 09, 2017	BUY	$12.17 - $16.3 $780,170 - $1.04 Million	64,106	64,106 $788,000

Others Institutions Holding LXRX

# of Institutions

131

Shares Held

240M

Call Options Held

617K

Put Options Held

286K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $313M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account